Merrill Lynch maintains Human Genome at neutral

Human Genome Sciences, Inc. was maintained by Merrill Lynch analyst Hari Sambasivam at a neutral rating after third-quarter results reported a lower-than-expected loss per share of $0.42, slightly better than Merrill Lynch estimates of $0.50. Revenues of $5.9 million were down compared to Merrill Lynch estimates of $6 million. The company announced enrollment in the Albuferon phase 2b trial was complete and that it repurchased $178 million of the 2007 convertible notes, ending the quarter with $598 million in outstanding debt. Shares of the Rockville, Md.-based biopharmaceutical company were up $0.18, or 2.19%, at $8.40 on volume of 3,845,247 shares versus the three-month running average of 3,723,460 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.